TY  - GEN
AB  - Immune checkpoint blockade (ICB) therapy targets checkpoint proteins to restore normal function to the immune system so that it can attack cancer cells. It is used successfully to treat a variety of cancers; however, many patients suffer from the development of immune-related adverse events (irAEs), which may affect any organ system and can be severe enough to cause the cessation of therapy. There is therefore great interest in understanding the mechanism of irAE development.  Our work contributes to the understanding of the role of Treg plasticity and Treg-Th17 balance in the context of ICB treatment and irAE development that will guide future research in the field.
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AU  - Fey, Rosalyn M.
AU  - Kulkarni, Rajan P.
DA  - 2024
DO  - 10.6083/bpxhc43653
DO  - doi
ID  - 43653
KW  - Immune Checkpoint Inhibitors
KW  - Cell Plasticity
KW  - Sequence Analysis, RNA
KW  - immune related adverse events (irAEs)
KW  - immune checkpoint blockade (ICB)
KW  - T cells
KW  - T cell plasticity
KW  - single cell RNA sequencing
L1  - https://digitalcollections.ohsu.edu/record/43653/files/ResearchWeek.2024.Fey.Rosalyn.pdf
L2  - https://digitalcollections.ohsu.edu/record/43653/files/ResearchWeek.2024.Fey.Rosalyn.pdf
L4  - https://digitalcollections.ohsu.edu/record/43653/files/ResearchWeek.2024.Fey.Rosalyn.pdf
LA  - eng
LK  - https://digitalcollections.ohsu.edu/record/43653/files/ResearchWeek.2024.Fey.Rosalyn.pdf
N2  - Immune checkpoint blockade (ICB) therapy targets checkpoint proteins to restore normal function to the immune system so that it can attack cancer cells. It is used successfully to treat a variety of cancers; however, many patients suffer from the development of immune-related adverse events (irAEs), which may affect any organ system and can be severe enough to cause the cessation of therapy. There is therefore great interest in understanding the mechanism of irAE development.  Our work contributes to the understanding of the role of Treg plasticity and Treg-Th17 balance in the context of ICB treatment and irAE development that will guide future research in the field.
PB  - Oregon Health and Science University
PY  - 2024
T1  - Computational assessment of T cell plasticity in immune related adverse events
TI  - Computational assessment of T cell plasticity in immune related adverse events
UR  - https://digitalcollections.ohsu.edu/record/43653/files/ResearchWeek.2024.Fey.Rosalyn.pdf
Y1  - 2024
ER  -